Mission Street and One Nucleus invite you to a panel discussion followed by networking.
Mission Street and One Nucleus invite you to a panel discussion followed by networking.
AI dominates the sector’s narrative, but this session goes beyond the headlines. We’ll explore the real‑world challenges and benefits of AI across the life sciences value chain, from early‑stage innovation and target discovery to clinical development, regulatory pathways and commercialisation.
We are seeking an enthusiastic, practical, and proactive Chief Building Services Technician to join our busy maintenance team. This is an exciting opportunity to contribute to a leading academic department, supporting cutting-edge research and teaching in a collaborative and supportive environment.
Neurotech is developing rapidly, with devices offering more precision and greater potential for scaling. Our flagship forum will provide a focused examination of the field’s direction by showcasing cutting-edge technological advances, as well as highlighting the importance of aligning clinical needs early in the development of technologies.
Entry in neurotech and translation pathways will be signposted through first-hand accounts of journeys and by highlighting ARIA calls, Cambridge NeuroWorks programming and further funding opportunities, plus investment perspectives.
About the role
Are you a machine learning researcher with expertise in deep generative modelling, eager to apply your methods to some of the most pressing challenges in global health? We are looking for a Research Associate to lead methodological development at the interface of deep learning and infectious disease modelling, working within a highly collaborative international team at Imperial College London.
What you would be doing
*Guest blog by Professor Alan M. Palmer, Chief Executive Officer, Elixa MediScience.
If you would like to submit a guest blog please email [email protected].
The industry promised AI would transform medicine. Instead, it delivered a speed boost nobody needed and a clinical failure rate nobody fixed.
The Research Team at Alzheimer’s Research UK (ARUK) is dedicated to funding ground breaking research to understand, diagnose, and cure dementia diseases. ARUK funds dementia research through an extensive portfolio of grant schemes and strategic initiatives both nationally and internationally.
*Guest blog by Pivotal. For more information on the information in this blog post please contact Natalia Farr - [email protected].
If you would like to submit a guest blog please email [email protected].
About the Opportunity
Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain.